Dysport®: Pharmacological properties and factors that influence toxin action

Toxicon

Volumn 54, Issue 5, 2009, Pages 683-689

  Pickett, Andy ^a  

^a IPSEN   (France)

Author keywords

Botulinum toxin complex; ; Botulinum toxin Type A; ; Botulinum toxin; ; Complex size; ; Diffusion of toxin; ; Dissociation; ; Dysport ; ; Spread

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BACTERIAL TOXIN; MUSCLE RELAXANT AGENT;

ARTICLE; BIOASSAY; DILUTION; DISSOCIATION; DRUG DIFFUSION; DRUG MEGADOSE; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; ELECTROMYOGRAPHY; EXPERIMENTAL MODEL; HUMAN; INJECTION; LD 50; LOW DRUG DOSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; CHEMISTRY; DIFFUSION; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION;

BACTERIAL TOXINS; BOTULINUM TOXIN TYPE A; DIFFUSION; NEUROMUSCULAR AGENTS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 68849099523     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxicon.2009.03.020     Document Type: Article

References (27)

1. ® (botulinum toxin type A) purified neurotoxin complex: local versus systemic muscle activity measurements in mice. Eur. J. Neurol. 2 Suppl. 3 (1995) 3-9
2. Aoki K.R., Ranoux D., and Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur. J. Neurol. 13 Suppl. 4 (2006) 10-19
3. Cliff S.H. Migration characteristics of botulinum neurotoxins. Cosmet. Dermatol. 20 Suppl. 3 (2007) 32-35
4. Cliff S.H., Judodihardjo H., and Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J. Cosmet. Dermatol. 7 (2008) 50-54
5. de Almeida A.T., and De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J. Cosmet. Laser Ther. 9 Suppl. 1 (2007) 17-22
6. de Almeida A.R.T., Marques E., de Almeida J., Cunha T., and Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A inpatients with forehead hyperhidrosis. Dermatol. Surg. 33 Suppl. 1 (2007) S37-S43
7. Eisele, K.-H., Taylor, H.V., 2008. Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions. In: Poster Presented at Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Baveno, Italy, June 12-15, 2008 (P164 published as abstract in Toxicon 51(Suppl. 1), 10).
8. Fick A. Ueber diffusion. Ann. Phys. 170 (1855) 59-86 (Also referenced in Bloomfield, V.A., 2000. Survey of biomolecular hydrodynamics. In: Shuster, T.M. (Ed.), On-line Biophysics Textbook Volume: Separations and Hydrodynamics)
9. Friday D., Bigalke H., and Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Naunyn-Schmeideberg'S Arch. Pharmacol. 365 Suppl. 2 (2002) R20
10. Hambleton P., and Pickett A.M. Potency equivalence of botulinum toxin preparations. J. R. Soc. Med. 87 (1994) 719
11. Hambleton P., Pickett A.M., and Shone C.C. Botulinum toxin: from menace to medicine. In: Ward A.B., and Barnes M.P. (Eds). Clinical Uses of Botulinum Toxins (2007), Cambridge University Press, Cambridge, Massachusetts
12. Hexsel D., Dal'Forno T., Hexsel C., Zechmeister do Prado D., and Lima M.M. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin Type A. Dermatol. Surg. 34 (2007) 1-8
13. Karsai S., Adrian R., Hammes S., Thimm J., and Raulin C. A randomized, double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch. Dermatol. 143 (2007) 1447-1449
14. Matsumura T., Jin Y., Kabumoto Y., Takegahara Y., Oguma K., Lencer W.I., and Fujinaga Y. The HA proteins of botulinum toxin disrupt intestinal epithelial intracellular junctions to increase toxin adsorption. Cell. Microbiol. 10 (2008) 355-364
15. Panjwani N., O'Keeffe R., and Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum J. 1 (2008) 153-166
16. Pickett A.M., and Hambleton P. Dose standardization of botulinum toxin. Lancet 344 (1994) 474
17. Pickett, A., Shipley, S., Panjwani, N., O'Keeffe, R., Singh, B.R., 2004. Characterisation and consistency of botulinum toxin type A-haemagglutinin complex used for clinical therapy. In: Poster Presented at the 41st Annual Meeting of the Interagency Botulinum Research Co-ordinating Committee, 27-29 October 2004, Baltimore.
18. Pickett A., and Caird D. Comparison of type A botulinum toxin products in clinical use. J. Clin. Pharm. Ther. 33 (2008) 327-328
19. Poulain B., Popoff M.R., and Molgo J. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. The Botulinum J. 1 1 (2008) 14-87
20. Rosales R.L., Bigalke H., and Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol. 13 Suppl. 1 (2006) 2-10
21. Sakaguchi G. Clostridium botulinum toxins. Pharmacol. Ther. 19 (1983) 165-194
22. Sugii S., and Sakaguchi G. Botulogenic properties of vegetables with special reference to the molecular size of the toxin in them. J. Food Safety 1 (1977) 53-65
23. Scott A.B., Rosenbaum A., and Collins C.C. Pharmacologic weakening of extraocular muscles. Invest. Ophthalmol. 12 (1973) 924-927
24. Schantz E.J., and Johnson E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 56 1 (1992) 80-99
25. Sharma S.K., and Singh B.R. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 43 (2004) 4791-4798
26. 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 42 (2003) 461-469
27. Wagman J., and Bateman J.B. Botulinum type A toxin: properties of a toxic dissociation product. Arch. Biochem. Biophys. 45 (1953) 375-383